

### About Deep Pharma Intelligence

**Deep Pharma Intelligence (DPI)** is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

**Deep Pharma Intelligence** is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** – two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

### Our Value Proposition:

#### Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets – technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

#### IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our dashboard to learn more:

[platform.dkv.global/dashboards/ai-for-drug-discovery](https://platform.dkv.global/dashboards/ai-for-drug-discovery)

#### Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.




### Cell Therapies in Healthcare Landscape Overview Q1 2023


This 62-page “Cell Therapies in Healthcare Landscape Overview Q1 2023” report represents the market analytics focused on the Cell Therapy Industry, clinical research and other aspects of pharmaceutical R&D. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry.

The current release includes insights about **400 Cell Therapy Industry companies** and **900+ investors** in the area of pharmaceutical and healthcare cell therapies.

#### Some of the key takeaways from this digest include:

- Cell Therapy is a rapidly growing industry that has the potential to revolutionize healthcare by providing new treatments for diseases that were previously untreatable.
- The market is valued at approximately \$12.56 billion in Q1 2023.
- In Q1 2023, The U.S. Food and Drug Administration approved new stem cell therapy. Gamida Cell's cell therapy Omisirge.
- The total market value of companies that use or develop new cell therapies is \$78B as of end of April 2023 which includes more than 125 companies that reached IPO and their number continue to rise.






DEEP  
PHARMA  
INTELLIGENCE

# Deep Pharma Intelligence

## Artificial Intelligence for Drug Discovery Landscape Overview Q4 2022



## Analysis of Top Cell Therapy Companies: R&D Maturity vs Application Focus

